Xu, Y., Chen, M., Gao, X., Huang, H., Chang, Y., Liu, X., Zhong, W., Zhao, J., Pan, R., Li, T., Wang, M. (2026). A phase 2 study of plinabulin (Plin)/docetaxel (Doc) plus pembrolizumab (Pemb) in metastatic NSCLC (mNSCLC) after acquired resistance (AR) to anti–PD-1/L1 alone or in chemotherapy combination: Efficacy and immunophenotyping.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8567